Interview: Chen Qiyu – Chairman, Fosun Pharma, China
Chen Qiyu, chairman of Fosun Pharma, discusses how the company is helping China achieve its ‘Healthy China…
Fosun Pharma
Last updated: 26.11.2018
Address: Fosun Commercial Building No. 2 Fuxing Road (East) Shanghai,
Zip Code：200010
,China
Tel: -23137935
Web: http://www.fosunpharma.com/
Company description
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”, stock code: 600196), was established in 1994 and listed on Shanghai Stock Exchange in August 1998. Now it has turned a leading listed company in Chinese pharmaceutical industry.
Fosun Pharma’s net profits have increased by 13.55 times since its 13-year listed and its annual compound growth rate has reached 24.26%. Meanwhile, its net assets and net profits are in front rank of the listed companies in Chinese pharmaceutical industry.
Fosun Pharma specializing in modern biological medical & health industry, has taken great opportunities of the rapid growth of China’s medical market and Chinese enterprises’ access to the world’s predominant medical market, and accelerated industry integration and implemented key product strategy by following the business principle of “Brand, Innovation, High-efficiency and Globalization” so as to realize stable operation and rapid development, at the same time, it has become a large pharmaceutical group on the aspect of R&D, innovation, marketing, merging & integration and team building by regarding R&D, manufacturing and distribution of the medicines as the core and taking the lead of the scale and market role in diagnostic medicines and medical instruments.
Products and services
Vertically integrated pharmaceutical company
Interviews
Related
China / Sinopharm Looks to mRNA Vaccines; Hong Kong Biotech Investment Continues to Boom; Another Big Manufacturing Investment for Lonza
The latest news from Chinese pharma and biotech, including news that state-owned Sinopharm is now developing its…
China / PhIRDA’s Song Ruilin on Strengthening Drug Supervision Capacity & Promoting Pharma Innovation
Song Ruilin, chairman of the China Pharmaceutical Innovation and Research Development Association (PhIRDA), picks…
China / CDE’s Drug Evaluation Report 2020: Part 1
The following is an overview from Accestra Consulting* of Part 1 of China’s Center for Drug Evaluation (CDE)’s…
China / Fosun Sales up 20%; MNC Price Manoeuvres Lead to Growth; Bayer Sees ‘Golden Age’ Ahead
The latest news from Chinese pharma, including Fosun Pharma’s 2021 interim results; how AstraZeneca, Bayer, Eli…
China / Striving for First-In-Class Drug Innovation with New Patent Law
In a comprehensive new piece, European Patent Attorney André Bourgouin and Adjunct Professor at CEIBS Eric…
China / Hong Chow Leaves Roche for Big New Role at Merck
In a big career move on a personal level and a sign of China’s continuing significance to global pharma, Hong…
China / Sinopharm Tops Brand Value Rankings; Simcere Splashes $565M on Alzheimer’s Drug; Innovent-Ascentage Tie-Up A Sign of Biotech Deals to Come?
The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant…
China / Fosun-Kite Yescarta Approval Signals Beginning of CAR-T Era
A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further…
China / First CAR-T Approval; AZ & Bayer Take VBP Hit; Lonza Boosts Manufacturing Capacity
The latest news from Chinese pharma, including a historic first approval for Fosun Kite’s CAR-T therapy Yescarta;…
China / New Country President for MSD Amid Changes at HQ & Access Challenges
MSD, which has had a presence in China since 1990, recently appointed Belgian national Anna van Acker to lead its…
China / A New Era of Reform Transforming Regulatory Professionals
Writing in the June edition of DIA’s Global Forum magazine, Harbour BioMed’s Fang Zhou, in conversation…
Hong Kong / HKEX’s Aim to Become World’s #1 Biotech Listing Hub & Challenges for New CEO
With three years having passed since the Hong Kong Stock Exchange (HKEX)’s decision to allow pre-revenue biotechs…
